Osteosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report

Published: April 29, 2022 Report Code: GMDGDHC22141IDB-ST

Select Item

Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue.

Osteosarcoma Drugs in Development market research report provides comprehensive information on the therapeutics under development for Osteosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects.

Key Targets in the Osteosarcoma Pipeline Market

The key targets in the Osteosarcoma pipeline market are Vascular Endothelial Growth Factor Receptor 2, Vascular Endothelial Growth Factor Receptor 3, Vascular Endothelial Growth Factor Receptor 1, Mast/Stem Cell Growth Factor Receptor Kit, Cells Expressing Ganglioside GD2, DNA Topoisomerase II, Fibroblast Growth Factor Receptor 1, and Platelet Derived Growth Factor Receptor Beta. Vascular Endothelial Growth Factor Receptor 2 has the highest number of pipeline products.

Osteosarcoma Pipeline Market, by Targets

Osteosarcoma Pipeline Market, by Targets

For more target insights, download a free report sample

Key MoA in the Osteosarcoma Pipeline Market

The key MoA in the Osteosarcoma pipeline market are Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Cytotoxic To Cells Expressing Ganglioside GD2, DNA Topoisomerase II Inhibitor, Programmed Cell Death 1 Ligand 1 Inhibitor and Fibroblast Growth Factor Receptor 1 Inhibitor. Vascular Endothelial Growth Factor Receptor 2 Inhibitor has the maximum number of pipeline products.

Osteosarcoma Pipeline Market, by MoA

Osteosarcoma Pipeline Market, by MoA

For more MoA insights, download a free report sample

Key RoA in the Osteosarcoma Pipeline Market

The key RoA in the Osteosarcoma pipeline market are intravenous, oral, subcutaneous, intravenous drip, parenteral, intratumor, intradermal, and inhalational. Intravenous has the majority number of pipeline products.

Osteosarcoma Pipeline Market, by RoA

Osteosarcoma Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Osteosarcoma Pipeline Market

The key molecule types in the Osteosarcoma pipeline market are small molecule, monoclonal antibody, gene-modified cell therapy, cell therapy, oncolytic virus, gene therapy, and monoclonal antibody conjugated.

Osteosarcoma Pipeline Market, by Molecule Types

Osteosarcoma Pipeline Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the Osteosarcoma Pipeline Market

The key companies in the Osteosarcoma pipeline market are AstraZeneca Plc, Bristol-Myers Squibb Co, Exelixis Inc, Advenchen Laboratories LLC, AntiCancer Inc, Atlanthera, Bayer AG, and CSPC Pharmaceutical Group Ltd. AstraZeneca Plc has the highest pipeline products.

Osteosarcoma Pipeline Market, by Companies

Osteosarcoma Pipeline Market, by Companies

To know more about companies, download a free report sample

Market report overview

Key targets Vascular Endothelial Growth Factor Receptor 2, Vascular Endothelial Growth Factor Receptor 3, Vascular Endothelial Growth Factor Receptor 1, Mast/Stem Cell Growth Factor Receptor Kit, Cells Expressing Ganglioside GD2, Platelet Derived Growth Factor Receptor Beta, DNA Topoisomerase II, and Fibroblast Growth Factor Receptor 1
Key MoA Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Cytotoxic To Cells Expressing Ganglioside GD2, DNA Topoisomerase II Inhibitor, Programmed Cell Death 1 Ligand 1 Inhibitor, and Fibroblast Growth Factor Receptor 1 Inhibitor
Key RoA Intravenous, Oral, Subcutaneous, Intravenous Drip, Parenteral, Intratumor, Intradermal, and Inhalational
Key molecule type Small Molecule, Monoclonal Antibody, Gene-Modified Cell Therapy, Cell Therapy, Oncolytic Virus, Gene Therapy, And Monoclonal Antibody Conjugated
Key companies AstraZeneca Plc, Bristol-Myers Squibb Co, Exelixis Inc, Advenchen Laboratories LLC, AntiCancer Inc, Atlanthera, Bayer AG, and CSPC Pharmaceutical Group Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteosarcoma (Oncology)
  • The pipeline guide reviews pipeline therapeutics for Osteosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities
  • The pipeline guide reviews key companies involved in Osteosarcoma (Oncology) therapeutics and enlists all their major and minor projects
  • The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteosarcoma (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies

  • Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage

  • Find and recognize significant and varied types of therapeutics under development for Osteosarcoma (Oncology)

  • Classify potential new clients or partners in the target demographic

  • Develop tactical initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics

  • Formulate corrective measures for pipeline projects by understanding Osteosarcoma (Oncology) pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline

Aadi Bioscience Inc
Actuate Therapeutics Inc
ADCendo ApS
Advanced BioDesign
Advaxis Inc
Advenchen Laboratories LLC
Allarity Therapeutics A/S
Anagenics Ltd
AntiCancer Inc
APEIRON Biologics AG
API Co Ltd
Astex Therapeutics Ltd
AstraZeneca Plc
Atlanthera
Aurora BioPharma Inc
Autolus Therapeutics Plc
Bayer AG
Bicycle Therapeutics Plc
BioAtla Inc
BioEclipse Therapeutics Inc
BioMarck Pharmaceuticals Ltd
BioMed Valley Discoveries Inc
Boehringer Ingelheim International GmbH
BrightPath Biotherapeutics Co Ltd
Bristol-Myers Squibb Co
CanBas Co Ltd
Cellectar Biosciences Inc
Cellestia Biotech AG
Chia Tai Tianqing Pharmaceutical Group Co Ltd
CorMedix Inc
CSPC Pharmaceutical Group Ltd
Curamir Therapeutics Inc
Dnatwo Inc
Eisai Co Ltd
Eleison Pharmaceuticals LLC
ENB Therapeutics LLC
Epeius Biotechnologies Corp
Exelixis Inc
GlaxoSmithKline Plc
GlycoMimetics Inc
Guangzhou Sinogen Pharmaceutical Co Ltd
Hebei Senlang Biotechnology Co Ltd
Hillstream BioPharma Inc
HRYZ (ShenZhen) Biotech Co
Hutchison MediPharma Ltd
Idera Pharmaceuticals Inc
ImmunityBio Inc
Incuron
Innova Therapeutics Inc
Intezyne Inc
Iovance Biotherapeutics Inc
Ipsen SA
Isofol Medical AB
Iterion Therapeutics Inc
ITM Isotopen Technologien Munchen AG
Jiangsu Hengrui Medicine Co Ltd
Joint Biosciences Ltd
K-Group Beta Inc
Komipharm International Co Ltd
Kyowa Kirin Co Ltd
MacroGenics Inc
Mana Therapeutics Inc
MD Biosciences GmbH
MediaPharma SRL
MedPacto Inc
Merck & Co Inc
Merck KGaA
MetCure Therapeutics LLC
Moleculin Biotech Inc
Nanjing Aimeifei Biomedical Technology Co Ltd
Nkarta Inc
Novartis AG
Oncolys BioPharma Inc
Oncotelic Therapeutics Inc
Ono Pharmaceutical Co Ltd
Orgenesis Inc
OS Therapies LLC
Peel Therapeutics Inc
Pfizer Inc
Pharma Mar SA
Pimera Inc
Provectus Biopharmaceuticals Inc
QSAM Therapeutics Inc
Radiopharm Theranostics Ltd
Reven Holdings Inc
Scancell Holdings Plc
Secura Bio Inc
Shanghai De Novo Pharmatech Co Ltd
Shionogi & Co Ltd
Singh Biotechnology LLC
Sorrento Therapeutics Inc
Taiho Pharmaceutical Co Ltd
Taithera Inc
Transcode Therapeutics Inc
Umoja BioPharma Inc
United Therapeutics Corp
Vaccinex Inc
Veana Therapeutics LLC
Y-mAbs Therapeutics Inc
Zentalis Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Osteosarcoma – Overview

Osteosarcoma – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Osteosarcoma – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Osteosarcoma – Companies Involved in Therapeutics Development

Osteosarcoma – Drug Profiles

Osteosarcoma – Dormant Projects

Osteosarcoma – Discontinued Products

Osteosarcoma – Product Development Milestones

Featured News & Press Releases

Apr 11, 2022: Adcendo presents data on uPARAP targeting ADCs in osteosarcoma PDX models at the 2022 AACR Annual Meeting

Jan 27, 2022: OS Therapies announces nationwide open enrollment of remaining 36 to 42 patients in phase IIb trial of OST-HER2 (Listeria monocytogenes) in recurred, resected osteosarcoma

Nov 03, 2021: OS Therapies receives Rare Pediatric Disease Designation (RDD) in osteosarcoma for OST-HER2 (Listeria monocytogenes)

Oct 25, 2021: OS Therapies doses first subject in Phase IIb osteosarcoma therapy trial

Jun 23, 2021: Children’s Cancer Research Fund supports AOST-2121 PhIIb clinical trial in recurred, resected osteosarcoma

Apr 26, 2021: Advaxis announces achievement of second milestone under ADXS-HER2 licensing agreement with OS Therapies

Mar 09, 2021: Allarity Therapeutics announces positive data from preclinical study of dovitinib in osteosarcoma

Feb 05, 2021: WPD Pharmaceuticals’ licensor announces 100% survival achieved in osteosarcoma lung metastases animal model of annamycin drug

Feb 02, 2021: Moleculin announces 100% survival achieved in osteosarcoma lung metastases animal model

Jan 26, 2021: OS Therapies receives trial approval from Children’s Oncology Group for AOST2121 / OST31-164-01 an open-label Phase 2 study of maintenance therapy with OST31-164 after resection of recurrent osteosarcoma

Jan 19, 2021: Advaxis announces receipt of funding milestone payment under ADXS-HER2 licensing agreement with OS Therapies

Nov 23, 2020: Hillstream BioPharma’s HSB-888 receives rare pediatric disease designation and orphan drug designation for osteosarcoma

Nov 19, 2020: Eisai to present new investigational data on LENVIMA (lenvatinib) in thyroid cancer and osteosarcoma at ESMO Asia 2020

Sep 24, 2020: Innova Therapeutics receives Rare Pediatric Disease Designation from the Food and Drug Administration (FDA) for IVT-8086 for the treatment of Osteosarcoma

Sep 11, 2020: Eisai to present abstracts on lenvatinib mesylate at ESMO Virtual Congress 2020

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Frequently asked questions

  • What are the key targets in the Osteosarcoma pipeline drugs market?

    The key targets in the Osteosarcoma pipeline market are Vascular Endothelial Growth Factor Receptor 2, Vascular Endothelial Growth Factor Receptor 3, Vascular Endothelial Growth Factor Receptor 1, Mast/Stem Cell Growth Factor Receptor Kit, Cells Expressing Ganglioside GD2, DNA Topoisomerase II, Platelet Derived Growth Factor Receptor Beta, and Fibroblast Growth Factor Receptor 1.

  • What are the key mechanisms of action in the Osteosarcoma pipeline market?

    The key MoA in the Osteosarcoma pipeline market are Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Cytotoxic To Cells Expressing Ganglioside GD2, DNA Topoisomerase II Inhibitor, Programmed Cell Death 1 Ligand 1 Inhibitor, and Fibroblast Growth Factor Receptor 1 Inhibitor.

  • What are the key RoA in the Osteosarcoma pipeline market?

    The key RoA in the Osteosarcoma pipeline market are intravenous, oral, subcutaneous, intravenous drip, parenteral, intratumor, intradermal, and inhalational.

  • What are the key molecule types in the Osteosarcoma pipeline market?

    The key molecule types in the Osteosarcoma pipeline market are small molecule, monoclonal antibody, gene-modified cell therapy, cell therapy, oncolytic virus, gene therapy, and monoclonal antibody conjugated.

  • What are the key companies in the Osteosarcoma pipeline drugs market?

    In the Osteosarcoma pipeline market the key companies are AstraZeneca Plc, Bristol-Myers Squibb Co, Exelixis Inc, Advenchen Laboratories LLC, AntiCancer Inc, Atlanthera, Bayer AG, and CSPC Pharmaceutical Group Ltd.

Osteosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Oncology reports
Pharmaceuticals
New
Immuno-oncology in pharma: neoepitope prediction
$250 | December 2023
Pharmaceuticals
New
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Pharmaceuticals
New
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
$250 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Osteosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Osteosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more